WO2005018620A2 - Utilisation d'un cofacteur de synthase d'oxyde nitrique (nos) pour traiter le dysfonctionnement sexuel - Google Patents

Utilisation d'un cofacteur de synthase d'oxyde nitrique (nos) pour traiter le dysfonctionnement sexuel Download PDF

Info

Publication number
WO2005018620A2
WO2005018620A2 PCT/EP2004/009543 EP2004009543W WO2005018620A2 WO 2005018620 A2 WO2005018620 A2 WO 2005018620A2 EP 2004009543 W EP2004009543 W EP 2004009543W WO 2005018620 A2 WO2005018620 A2 WO 2005018620A2
Authority
WO
WIPO (PCT)
Prior art keywords
nos
treatment
cofactor
agent
sexual
Prior art date
Application number
PCT/EP2004/009543
Other languages
English (en)
Other versions
WO2005018620A3 (fr
Inventor
Wilhelm Bloch
Frank Sommer
Theo Klotz
Original Assignee
Cell Center Cologne Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Center Cologne Gmbh filed Critical Cell Center Cologne Gmbh
Publication of WO2005018620A2 publication Critical patent/WO2005018620A2/fr
Publication of WO2005018620A3 publication Critical patent/WO2005018620A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Definitions

  • nitric oxide synthase (NOS) cofactor for the treatment of sexual dysfunction
  • the present invention relates to the technical field of treatment of sexual dysfunction.
  • the present invention relates to the use of a nitric oxide synthase (NOS) cofactor for the preparation of a pharmaceutical composition for the treatment of sexual dysfunction of a subject, including both male erectile dysfunction and female sexual dysfunction, including methods and formulations for the use and administration of the same.
  • NOS nitric oxide synthase
  • Sexual dysfunctions are relatively common in the general population; see O'Donohue et al., Clin. Psychol. Rev. 17 (1997), 537-566.
  • the disorder may relate to seeking sexual behavior (proceptivity) and/or to acceptance of sexual behavior, accompanied by sexual arousal (receptivity).
  • the prevalence of sexual problems is higher in populations receiving medicaments, in particular antidepressants and anti- hypertensives.
  • a need for pharmacotherapy for sexual dysfunction is increasing, but there has been very little research effort directed at finding drugs to treat sexual dysfunction.
  • Sexuai dysfunctions include erectile dysfunctions (ED) of organic and psychogenic origin (Benet and Melman, Urol. Clin. N. Amer. 22 (1995), 699-709) as well as hypoactive sexual desire disorders, sexual arousal disorders, anorgasmy and sexual pain disorders (Berman et al., Urology 54 (1999), 385-391).
  • impotence can be defined as an inability to achieve penile erection or ejaculation. Its prevalence is claimed to be between 2 % and 7 % of the human male population, increasing with age up to 50 years, and between 18 % and 80 % between 55 and 80 years of age. In the USA alone, for example, it has been estimated that there are up to 10 million impotent males, with the majority suffering from problems of organic rather than of psychogenic origin. Although many different drugs have been shown to induce penile erection, they were only effective after direct injection into the penis, e.g., intraurethrally or intracavernosally (i.e.) and were not approved for erectile dysfunction.
  • US-A-5, 576,290 discloses peptides which are stated to induce erection, but they have to be given subcutaneously, e.g., by injection, and if an excessive dose is given they produce an exaggerated erectile response and stomach discomfort. Impotence treatment was revolutionized by the unexpected discovery that cGMP PDE5 inhibitors, e.g. pyrazolo[4,3-d]pyrimidin-7-ones were useful in the treatment of erectile dysfunction and could be administered orally, therefore obviating the disadvantages associated with l c. administration.
  • cGMP PDE5 inhibitors e.g. pyrazolo[4,3-d]pyrimidin-7-ones were useful in the treatment of erectile dysfunction and could be administered orally, therefore obviating the disadvantages associated with l c. administration.
  • intracavernous prostaglandin injection therapy is also a well-established component of the therapy cascade. All treatment options entail specific side effects or contraindications; see Table 1. Table 1: Treatment options, side effects and problems, contraindications
  • sildenafil (Viagra ⁇ ).
  • the success rate for sildenaf ⁇ l varies in the group of ED patients with an organically caused disease from 43 % in patients who have undergone radical prostatectomy to 85 % in patients with a neurologically related disorder, and amounts to an average of 82 % (range 43-85 %, 100 mg) (Gresser and Gleiter, Eur. J. Med. Res. 7 (2002), 435-446).
  • a certain proportion of the patient population, such as diabetics, does not gain significant benefit from PDE5 inhibitors, possibly due to a lack of endogenous nitric oxide.
  • Rho-kinase inhibitors Rho-kinase inhibitors
  • soluble guanylate cyclase activators nitric oxide- releasing PDE5 inhibitors
  • vasoactive agents for treatment of female sexual arousal disorder.
  • the underlying assumption is that genital blood flow is responsible for female arousal, and thus vasoactive agents that increase flow could improve arousal deficiency (Davis, Curr. Psychiatry Rep. 2 (2000), 21 1-214).
  • Preliminary results from small pilot studies suggest vasoactive agents may be efficacious.
  • Laboratory evidence indicates that phosphodiesterase type 5 modulates human clitoral smooth muscle tone (Park, Biochem. Biophys. Res. Commun. 249 (1998), 612-617).
  • phosphodiesterase inhibitors such as sildenafil might have impact on sexual response.
  • the present invention is based on the realization that substances that act as a cofactor of nitri ⁇ oxide synthase (NOS) have utility in the treatment of sexual dysfunction, including th ⁇ behavioral component thereof, in both male and female subjects.
  • NOS nitri ⁇ oxide synthase
  • they cai provide a treatment for erectile dysfunctions of organic and psychogenic origin as well a: hypoactive sexual desire disorders, sexual arousal disorders, anorgasmy and sexual pair disorders.
  • the invention therefore provides a method of treating sexual dysfunction which comprise: administering to a subject suffering therefrom and in need of treatment an effective amount of ⁇ cofactor of nitric oxide synthase (NOS); said cofactor preferably being tetrahydrobiopterir (BH4) or a precursor or analogue thereof.
  • NOS cofactor ol nitric oxide synthase
  • NOS cofactor in accordance with the present invention may be accompanied b) the use of further therapeutic agents such as a phosphodiesterase (PDE) inhibitor, a prostaglandir (PG), apomorphine, papaverin or phentolamin. Therefore, the present invention also concerns z pharmaceutical composition comprising a NOS cofactor such as BH4 and a second therapeutic such as sildenafil or vardenafil.
  • PDE phosphodiesterase
  • PG prostaglandir
  • apomorphine papaverin or phentolamin. Therefore, the present invention also concerns z pharmaceutical composition comprising a NOS cofactor such as BH4 and a second therapeutic such as sildenafil or vardenafil.
  • substances and compositions which can improve female sexual function and maintenance of functional and structural integrity ol vaginal and clitoral tissue.
  • Those substances and compositions are based on nitric oxide synthase enzyme cofactors, in particular tetrahydrobiopterin (BH ), its precursors and its analogues.
  • BH nitric oxide synthase enzyme cofactors
  • eNOS endothelial NOS
  • BH4 is an important factor for eNOS-dependent NO release. A reduction or lack of BH4 leads tc a dysfunction of eNOS, which causes a switch from NO release to formation of oxygen free radicals.
  • BH4 should have direct effects for improvement of female sexual function alone or in combination with othei downstream working therapeutics like PDE-5 inhibitors and a long-time effect by prevention oi oxygen free radical damage of vaginal and clitoral tissue.
  • Two further advantages of BH4 treatment should be also considered, the low side effects and the positive effects on disease which are often associated with female sexual dysfunction.
  • a further aspect of the present invention relates to the use of nitric oxide synthase cofactors such as tetrahydrobiopterin (BH4), and its precursors and analogues, to manufacture compositions for improving erectile function and maintenance of functional and structural integrity of corpus cavernosum tissue.
  • Those compositions can be used in systemic administration as well.
  • the therapeutic options in use until now for the treatment of erectile dysfunction (ED) do not prevent the condition underlying erectile dysfunction in accordance with the present invention: namely, the reduced or diminished NO release by endothelial NOS (eNOS).
  • present-day therapies are unable to ameliorate ED in a distinct percentage of patients. Furthermore, no long-term protection of cavernosal tissue is obtained.
  • a causal therapy using BH4, or its precursors or analogues, can improve erectile function and prevent injury of erectile tissue.
  • BH4 should hence have beneficial effects for the improvement of erectile function, either alone or in combination with other downstream therapeutics such as PDE5 inhibitors, in addition to the long-term effect of preventing oxygen free radical damage of erectile tissue.
  • PDE5 inhibitors include PDE5 inhibitors.
  • Two further advantages of BH4 treatment should also be considered: the low side effects and the positive effects on diseases that are often associated with erectile dysfunction.
  • a NOS cofactor such as BH4
  • Another object of the invention is to provide the use of a NOS cofactor as single or co- medication for the treatment of interstitial cystitis, low bladder capacity disorders or of micturition disorders as urge incontinence.
  • the present invention relates to the use of a nitric oxide synthase (NOS) cofactor for the preparation of a pharmaceutical composition for the treatment of sexual dysfunction of a subject.
  • NOS nitric oxide synthase
  • said cofactor is tetrahydrobiopterin (BH4) or a precursor or analogue thereof
  • the present invention is based on the observation that the nitric oxide synthase (NOS) cofactor tetrahydrobiopterin and its precursors can be used to produce a substance that can improve erectile function and maintenance of functional and structural integrity of corpus cavernosum tissue; see Example 2.
  • NOS nitric oxide synthase
  • patients with erectile dysfunction have been treated for 3 to 6 months with BH4 or sepiapterin, and the alteration in erectile function was monitored.
  • the sole effect of BH4 or sepiapterin, as well as the effect of BH4 or sepiapterin in combination with a PDE5 inhibitor has been investigated in erectile dysfunction and it could surprisingly be shown that BH4 considerably improves penile response.
  • BH4 its precursors and its analogues could improve erectile function by enhancing NO-dependent relaxation of corpus cavernosum smooth muscle and protect corpus cavernosum tissue from degeneration, which entails a reduction of erectile tissue when smooth muscle and endothelium are replaced by non-erectile fibrous tissue.
  • the substances can be used alone or in combination with other substances that work by means of increased activation or support of the NO/cGMP pathway.
  • BH4 its precursors or its analogues
  • the therapeutic use of BH4, its precursors or its analogues could ameliorate the NOS-dependent imbalance of NO release and oxygen radical formation in the human corpus cavernosum.
  • This could improve erectile function by enhancing NO-dependent relaxation of corpus cavernosum smooth muscle and protect corpus cavernosum tissue from degeneration, which entails a reduction of erectile tissue when smooth muscle and endothelium are replaced by non-erectile fibrous tissue.
  • the structural and physiological intercourses makes it very likely that oxygen free radicals play a role in the aetiology of female sexual dysfunction as well.
  • the present invention relates to methods for treating sexual dysfunction in a patient comprising administering to the patient an effective amount of BH4 or of derivatives of BH4.
  • sexual dysfunction is used herein in its broadest sense as it applies to both males and females. Generally, the term denotes the inhibition of one or more of the phases of sexual response including appetite, excitement, orgasm or resolution.
  • sexual dysfunction encompasses, for example, decreased sexual desire, the inability to sustain an erection, the inability to ejaculate and/or the inability to experience orgasm.
  • sexual dysfunction refers, for example, to pain or discomfort during sexual intercourse, diminished vaginal lubrication, delayed vaginal engorgement, increased time for arousal, diminished ability to reach orgasm, and/or diminished clitoral sensation.
  • treatment of sexual dysfunction as used herein in reference to both males and females encompasses the enhancement of sexual pleasure and stimulation.
  • an orgasmic woman seeking a more pronounced sexual response can be treated according to the present methods.
  • a more pronounced sexual response or enhancement of sexual pleasure includes, but is not limited to, decrease in the amount of foreplay, decrease in the period between orgasms, decrease in the intercourse time required for orgasm, and achievement of multiple orgasms.
  • patient refers generally to both male and female members of the animal kingdom. Because the present methods include inducement of sexual stimulation, they have application in, for example, animal husbandry. The present methods are therefore not limited to applications for humans.
  • said cofactor is a compound of formula (I):
  • R and R each represent a hydrogen atom or, taken together with each other, represent a single bond
  • R 3 represents -CH(OH)CH(OH)CH 3 , -CH(OCOCH 3 )CH(OCOCH 3 )CH 3 , -CH , -CH 2 OH, or a phenyl group when R 1 and R 2 each represent a hydrogen atom, or -COCH(OH)CH 3 when R and R together represent a single bond, or a pharmaceutically acceptable salt thereof; or a pharmaceutically acceptable composition containing either entity.
  • R 3 is L-erythro-CH(OH)CH(OH)CH 3 .
  • said compound is selected from the group consisting of (6R)-L-erythro-5,6,7,8-tetrahydrobiopterin (BH4), (6R,S)-5,6,7,8- tetrahydrobiopterin, ,2'-diacetyl-5,6,7,8-tetrahydrobiopterin, sepiapterin, 6-methyl-5,6,7,8- tetrahydropterin, 6-hydroxymethyl-5,6,7,8-tetrahydropterin, 6-phenyl-5,6,7,8-tetrahydropterin, or a precursor of any one thereof.
  • said compound is a 5,6,7,8- tetrahydrobiopterin or a salt thereof; e.g., BH4 or a salt thereof.
  • the above described compounds of the formula (I) used as effective ingredients in the present invention are mostly known compounds; see, for example, European patent application EP 0 908 182-A and Japanese patent publication disclosures (KOKAI) Nos. 25323/84, 76086/84, 277618/86 and 267781/88.
  • These compounds may be used as appropriate salts with pharmacologically non-toxic acids, including mineral acids such as hydrochloric acid, phosphoric acid, sulfuric acid, boric acid; and organic acids such as acetic acid, formic acid, maleic acid, fumaric acid, mesylic acid.
  • EP 0 908 182-A compounds of formula (I) are described in context with preventing or ameliorating diseases caused by dysfunction of NOS, in particular for the treatment of hypertension and renal diseases.
  • diseases caused by dysfunction of NOS in particular for the treatment of hypertension and renal diseases.
  • specific utility of those compounds for the treatment of sexual dysfunction such as erectile dysfunction or dysfunction of sexual arousal has neither been considered nor suggested.
  • a pharmaceutical composition of the present invention is prepared by formulating a NOS cofactor such as a compound of formula (I) with generally used carriers by conventional procedures into a dosage form suitable for oral, intracavernous, rectal or parenteral administration (including administration into vein and cerebrospinal fluid).
  • the carriers used for these pharmaceutical formulations generally include excipients, binders, disintegrators, etc. depending on the dosage form chosen.
  • excipients include starch, lactose, sucrose, glucose, mannitol and cellulose
  • examples of binders include polyvinylpyrrolidone, starch, sucrose, hydroxypropyl cellulose, Arabic gum.
  • disintegrators examples include starch, agar, gelatin powder, cellulose, CMC, but any other conventional excipients, binders and disintegrators may also be used.
  • the pharmaceutical composition of the present invention may also contain antioxidants for stabilizing effective ingredients.
  • Antioxidants can be appropriately selected from those conventionally used for pharmaceutical preparations, such as ascorbic acid, N-acetylcysteine, L-cysteine, dl-alpha-tocopherol, natural tocopherol etc. They are used in an amount that stabilizes the active ingredient(s) (one or more) and generally, the ratio of an antioxidant averages between 0.2 and 2.0 parts by weight to 1 part by weight of the active ingredient(s).
  • Formulations of the present invention suitable for oral administration may be provided in the form of tablets, sublingual tablets, capsules, powders, granules or fine granules, or suspensions in a non-aqueous liquid such as syrups, emulsions or draft (pro re nata preparation) that contain the prescribed amount of the active ingredient (one or more).
  • a non-aqueous liquid such as syrups, emulsions or draft (pro re nata preparation) that contain the prescribed amount of the active ingredient (one or more).
  • granules are prepared by homogeneously mixing the active ingredient(s) (one or more) with one or more auxiliary ingredients such as carriers and antioxidants as mentioned above, followed by granulation and sieving to uniform grain size.
  • Tablets can be prepared by compressing or molding the active ingredient(s) (one or more) optionally together with one or more auxiliary ingredients.
  • Capsules are prepared by filling powder or granules of active ingredient (one or more) optionally mixed homogeneously with an auxiliary ingredient (one or more) into appropriate capsules using a capsule filling machine or the like.
  • Formulations for rectal administration can be provided as suppositories using conventional carriers such as cocoa butter.
  • Parenteral formulations can be provided as dry solids of the active ingredient(s) (one or more) sealed in a nitrogen-filled sterilized containers. Such dry solid preparations can be administered to patients after dispersing or dissolving them into a determined amount of sterilized water just prior to administration.
  • antioxidants as mentioned above may preferably be added to a mixture of an effective ingredient and conventional carriers, and optionally one or more auxiliary ingredients selected from buffers, flavors, surfactants, viscosants, lubricants, etc. can also be added, if needed.
  • the dosage of active ingredients, i.e. NOS cofactor may vary with the administration route, the symptom to be treated and the patient condition, and the final determination of the dosage should be made by an attendant physician.
  • an appropriate dosage for treating erectile dysfunctions ranges from 0.1 to 1000 mg/kg (b.w.)/day, and representative optimal dosage is 10 to 100 mg/kg (b.w.)/day.
  • a desired dosage of said active ingredients may be administered once a day or in divided doses of two to four times a day at appropriate intervals.
  • Active ingredients may be administered alone or in combination with pharmaceutical formulations containing other active ingredients suitable for the disease under treatment to facilitate control of the dosage, for example.
  • formulations of the present invention may contain at least one auxiliary effective ingredient selected from the substrates or coenzyme or cofactor for NOS such as L-arginine, flavins, for example, FAD, FMN, etc., or calcium. More excellent therapeutic effects can be expected when NOS cofactors are mixed with these effective ingredients than when used alone.
  • the proportion of each of said auxiliary effective ingredients in formulations of the present invention is not specifically limited.
  • the weight ratio of at least one formulation selected from L- arginine, flavins and calcium to 1 part of the NOS cofactor such as compounds of formula (I) may be within the range from 0.1 to 10, preferably 0.5 to 2.
  • an appropriate dosage of such mixed formulations for treating sexual dysfunctions ranges from 0.1 to 1000 mg/kg (b.w.)/day, preferably 10 to 100 mg/kg (b.w.)/day, in terms of the total amount of active ingredients.
  • a physician may appropriately choose formulations containing compounds of formula (I) alone or in combination with other active ingredients, depending on the age, condition or other factors of the patient.
  • the most preferable active ingredients used in the present invention are (6R)-L-erythro-5,6,7,8- tetrahydrobiopterin (BH4) and salts thereof, but (6R,S)-5,6,7,8-tetrahydrobiopterin, l',2'- diacetyl-5,6,7,8-tetrahydrobiopterin, sepiapterin, 6-methyl-5,6,7,8-tetrahydropterin, 6- hydroxymethyl-5,6,7,8-tetrahydropterin or 6-phenyl-5,6,7,8-tetrahydropterin and salts thereof may also be used.
  • BH4 naturally occurring component is most preferable.
  • BH4 dihydrochloride has little toxicity to rats judging from the fact that an acute toxicity was more than 2 g/kg (b.w.).
  • An optically inactive analogue, (6R,S)-5,6,7,8-tetrahydrobiopterin is also only slightly toxic as reported in Japanese Patent Public Disclosure No. 25323/84 for the treatment of Parkinson's disease, so that it can also be used for the therapy according to the present invention.
  • Other compounds of formula (I) also show little or no acute toxicity.
  • the appropriate concentration of the therapeutic agent might be dependent on the particular agent.
  • the therapeutically effective dose has to be compared with the toxic concentrations; the clearance rate as well as the metabolic products play a role as do the solubility and the formulation.
  • Therapeutic efficacy and toxicity of compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., ED50 (the dose therapeutically effective in 50 % of the population) and LD50 (the dose lethal to 50 % of the population).
  • the dose ratio between therapeutic and toxic effects is the therapeutic index, and it can be expressed as the ratio LD50/ED50.
  • the pharmaceutical composition may be administered by any means known in the art, including administration by intravenous and intracavernous injection, for administration through mucous membranes, buccal or sublingual administration, oral administration, dermal administration, inhalation administration and nasal administration.
  • administration is effected by systemic administration of a metered amount of a formulation including an aqueous buffer, which buffer may be a saline or citrate buffer.
  • the composition is formulated as a tablet and comprises ascorbic acid and/or N-acetyl-L-cysteine as a diluent.
  • inert pharmaceutically acceptable carriers can be either solid or liquid.
  • Solid form preparations include powders, tablets, dispersible granules, capsules, sachets, and suppositories.
  • a solid carrier can be one or more substances which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, or tablet disintegrating agents; it can also be an encapsulating material.
  • the carrier is a finely divided solid which is in a mixture with the finely divided active component.
  • the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
  • the powders and tablets preferably contain 5 % to about 70 % of the active component.
  • Suitable carriers are magnesium carbonate, magnesium stearate, talc, lactose, sugar, pectin, dextrin, starch, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, a low-melting wax, cocoa butter, and the like.
  • Liquid form preparations include solutions, suspensions, and emulsions. Sterile water or water- propylene glycol solutions of the active compounds may be mentioned as an example of liquid preparations suitable for parenteral administration. Liquid preparations can also be formulated in solution in aqueous polyethylene glycol solution.
  • Aqueous solutions for oral administration can be prepared by dissolving the active component in water and adding suitable colorants, flavoring agents, stabilizers, and thickening agents as desired.
  • Aqueous suspensions for oral use can be made by dispersing the finely divided active component in water together with a viscous material such as natural synthetic gums, resins, methyl cellulose, sodium carboxymethyl cellulose, and other suspending agents known to the pharmaceutical formulation art.
  • the pharmaceutical preparation is in unit dosage form.
  • the preparation is divided into unit doses containing appropriate quantities of the active component.
  • the unit dosage form can be a packaged preparation, the package containing discrete quantities of the preparation, for example, packeted tablets, capsules, and powders in vials or ampoules.
  • the unit dosage form can also be a capsule, sachet, or tablet itself, or it can be the appropriate number of any of these packaged forms.
  • a low-melting wax such as a mixture of fatty acid glycerides and cocoa butter is first melted and the active ingredient is dispersed therein by, for example, stirring. The molten homogeneous mixture is then poured into conveniently sized moulds and allowed to cool and solidify.
  • the active ingredient(s) can be designed to be released in an active form over time.
  • General methods for the preparation of retard compositions, i.e. compositions for controlled release of drugs are known in the art; see, e.g., Gupta et al., Drug Discov. Today 7 (2002), 569-579.
  • Controlled release can be achieved for example by chemical modification of the agent or application as a prodrug, whereby the prodrug is inactive and rendered active by a metabolic reaction at the site of application.
  • various formulations of agents are possible tailoring the release according to needs.
  • the therapeutic agent can be cross-linked with the resorbable substance such that it is released when the substance is degraded.
  • Compositions that are adapted for oral administration to humans are preferred, especially such compositions in unit dosage form.
  • the pharmaceutical compositions of the present invention can be used for the treatment of sexual dysfunction of both, male and female.
  • Female sexual dysfunctions are highly prevalent but not well defined and understood. Existing definitions and classifications of female sexual dysfunctions are reevaluated and revised at present. Contemporary classification was expanded to include psychogenic and organic causes of desire, arousal, orgasm and sexual pain disorders.
  • Female sexual dysfunction (FSD) was recently recognized as arising from multiple organic etiologies; it is not primarily a psychological symptom as believed previously. A symptom-related complex resulting in physiologic changes, FSD can respond to either treatment of the underlying condition or supportive measures (Lightner, Mayo. Clin. Proc. 77 (2002), 698-702).
  • Penile erection is a hemodynamic process, involving increased arterial inflow and restricted venous outflow, in coordination with corpus cavernosum smooth muscle relaxation (Anderson et al., Physiol. Rev. (1997), 191-236). Although this process is generally accepted to be under neuroregulatory control (Pickert et al., Br.
  • endothelial NO synthase is one of the main sources of nitric oxide in the cavernosal tissue, which is then available in endothelial cells and cavernosal smooth muscle cells (Bloch et al, Urol. Res. 26 (1998), 129-135). Also in female rats eNOS was localized to vascular endothelium and perivascular smooth muscle fibers of vaginal tissue and N-NOS immunoreactivity was localized to nerve fibers supplying vaginal smooth muscle, perivascular nerve plexuses, and lamina intestinal.
  • NOS The expression of the NOS isoform in the rat vaginal tissue is estrogen-dependent and it was suggested that NOS is involved in estrogen deficiency-dependent apoptosis and vaginal atrophy.
  • This cellular distribution of NOS in the rat vagina suggests that NO may modulate both vaginal blood supply and vaginal smooth musculature.
  • Estrogen appears to play a critical role in concomitantly regulating vaginal NOS expression and apoptosis in nerves, smooth muscle, vascular endothelium, and epithelium of the rat vagina (Berman et al., Urology 51 (1998), 650-656).
  • Giraldi et al. Int. J. Impot. Res.
  • NO-cGMP pathway may be useful to treat female sexual dysfunction.
  • medication or co-medication with NOS cofactors such as BH4 and analogues thereof offers a promising solution here.
  • the pharmaceutical compositions described herein are useful in the treatment of female sexual dysfunction, and this includes female sexual dysfunction associated with hypoactive sexual desire disorders, sexual arousal disorders, orgasmic disorders or anorgasmy, or sexual pain disorders.
  • This aspect of the present invention is based on the observation that the therapeutic use of BH4, its precursors or its analogues could ameliorate the NOS-dependent imbalance of NO release and oxygen radical formation in the human female outer sexual organs.
  • This could ameliorate female sexual function by improved NO-dependent blood flow, smooth muscle relaxation and sensory function as well as degeneration, which causes a reduction of functional vaginal tissue by replacement of nerve fibers, smooth muscle and endothelium by non-functional fibrous tissue.
  • the NOS cofactors can be used alone or in combination with other substances, which work by increased activation or support of the NO/cGMP pathway.
  • Advantages of the present invention comprise, inter alia, that the treatment with NOS cofactors such as BH4, its precursors or its analogues, have only limited side effects.
  • NOS cofactors such as BH4, its precursors or its analogues
  • treatment with BH4 is a causal therapy, directly linked to the impaired endothelial NOS activity leading to female sexual dysfunction, and in a BH4-saturated condition no further effect of BH4 treatment for NO release by endothelial NOS occurs.
  • NOS cofactors such as BH4
  • BH4 is a causal therapy, directly linked to the impaired endothelial NOS activity leading to female sexual dysfunction, and in a BH4-saturated condition no further effect of BH4 treatment for NO release by endothelial NOS occurs.
  • oxygen free radical reaction products such as 8-isoprostane and a strong effect of oxygen radicals for cell and tissue vitality.
  • Sexual arousal disorders can be characterized as persistent or recurrent inability to achieve or maintain adequate sexual excitement, causing personal distress.
  • Common problems include lack of or diminished vaginal lubrication, decreased clitoral and labial sensation, decreased clitoral and labial engorgement and lack of vaginal smooth muscle relaxation.
  • Orgasmic disorders can be characterized as persistent or recurrent difficulty or delay in attaining orgasm after adequate sexual stimulation and arousal, causing personal distress.
  • Sexual pain disorders can be characterized by dyspareunia, (characterized by recurrent or persistent genital pain associated with sexual intercourse), vaginismus (characterized by recurrent or persistent involuntary spasm of the muscles of the outer third of the vagina which interferes with vaginal penetration, causing personal distress) and other pain disorders (characterized by recurrent or persistent genital pain induced by non-coital sexual stimulation).
  • the said dysfunction is related to the maintenance of functional and structural integrity of clitoral and vaginal tissue.
  • the pharmaceutical composition may be administered in accordance with the dosage regimen described above.
  • the administration of said composition to the female can be in a dosage which is in the range of from 0.1 to 500 mg/kg/day and wherein said administration is at intervals of 1 to 3 times a day during a period of at least 12 weeks; said treatment regimen may be combined and/or repeated at one or several intervals.
  • the dosage is in the range of 10 to 100 mg/kg/day.
  • the present invention comprises the use of a second agent capable of ameliorating sexual dysfunction for the preparation of a pharmaceutical composition, see also supra, wherein if said NOS cofactor and said second agent are comprised in a first and second pharmaceutical composition, said first and second pharmaceutical composition are applicable simultaneously or sequentially.
  • NOS cofactors can generally be used as part of a medicament in combination with one or more other therapeutic agents such as a vasodilator, hormone therapy or neurotransmitter modulator used or tested in the treatment of sexual dysfunction.
  • Vasodilators for the treatment of sexual dysfunctions of organic (rather than psychogenic) origin act at the penis, clitoris or vagina level on local blood flow or lubricant secretions.
  • Vasodilators useful for the treatment of sexual dysfunction include alprostadil or phentolamine, NO (nitric oxide) enhancers such as L-arginine, and PDE5 inhibitors such as sildenafil or a pharmaceutically acceptable salt thereof (see EP 0 702 555 and references cited therein; Scrip's Complete Guide to Women's Healthcare (2000), 194-205; Sachs, Neuroscience and Biobehavioral Review 24 (2000), 541-560, Benet and Melman, Urol. Clin. N. Amer.
  • VIP Vaso-Intestinal Peptide
  • angiotensin-2 receptor antagonists such as losartan
  • Hormone therapies useful in the treatment of sexual dysfunction of organic and psychogenic nature include modulators of steroid hormones, steroid hormones or hormone products (including synthetic hormones) including estrogen (Scrip's Complete Guide to Women's Healthcare (2000), 194-205), or androgens such as testosterone (Scrip's Complete Guide to Women's Healthcare (2000), 194-205; Sachs, Neuroscience and Biobehavioral Review 24 (2000), 541-560), which act in areas of the CNS associated with sexual desire and sexual arousal (Wilson, Pharmacological targets for the control of male and female sexual behaviour. In: Sexual Pharmacology, Riley et al. (Eds.), Clarendon Press, Oxford (1993), 1-58). Furthermore, melanocortin receptor-specific compounds have been explored for use in treatment of sexual dysfunction as described and summarized in US patent US-A-6, 579,968.
  • Neurotransmitter modulators useful in the treatment of both psychogenic and organic sexual dysfunction include neurotransmitter agonists and antagonists such as catecholamine agonists such as the D2 agonist quinelorane, selective dopamine D3 receptor agonists (see WO03/051370), 5HT2 antagonists such as ritanserin, monoamine synthesis modifiers such as treatments that reduce endogenous 5HT activity, including inhibition of 5HT synthesis using parachlorophenylalanine, monoamine metabolism or uptake modifiers that inhibit catecholamine metabolism or uptake, such as tricyclic antidepressants, e.g. imipramine; see Wilson (1993), supra.
  • catecholamine agonists such as the D2 agonist quinelorane
  • selective dopamine D3 receptor agonists see WO03/051370
  • 5HT2 antagonists such as ritanserin
  • monoamine synthesis modifiers such as treatments that reduce endogenous 5HT activity, including inhibition of 5HT synthesis using parachlorophenylalanine
  • All of the above mentioned compounds and therapies can be combined and used with a NOS cofactor for the treatment of a sexual dysfunction in accordance with the present invention.
  • the use of this combination therapy includes the preparation of therapies that would allow administration of both components of the medicament, i.e. a NOS cofactor and a vasodilator, hormone therapy medicament or neurotransmitter modulator medicament in a single dose.
  • a preferred formulation would allow oral administration.
  • administration by suppository, cream, transdermal patch or injection is also part of this invention.
  • the invention envisages formulations which allow administration of the NOS cofactor via a separate route to that of the vasodilator, hormone therapy medicament or neurotransmitter modulator medicament.
  • routes could include, for example, oral administration of the NOS cofactor and transdermal patch application of the vasodilator.
  • transdermal delivery system designed to deliver therapeutic levels of drugs which address sexual dysfunction caused by impotency in males and vaginal dryness in females to specific sites below the dermal level of the skin is described in US patent application US2003/138494.
  • a kit in which unit doses of NOS cofactor occur in association with unit doses of the vasodilator, hormone therapy medicament or neurotransmitter modulator medicament.
  • kits where a NOS cofactor is formulated as a tablet, capsule or other unit dosage form for oral administration and the vasodilator is provided as a transdermal patch the two dosage forms could be provided in the form of a two-row tear-off strip in which compartments containing the tablets, etc. occur above compartments containing the transdermal patches.
  • Other forms of packaging in which the two dosage forms are spatially associated so as to make it easy for patients to take them together and to be reminded when they have done so will readily occur to those skilled in the art.
  • the kit will also contain instructions as to when and how the individual components of the kit should be administered.
  • said second agent is preferably a phosphodiesterase (PDE) inhibitor, a prostaglandin (PG), papaverin or phentolamin, wherein said PDE inhibitor is preferably a PDE5 or PDE6 inhibitor and said PG is PGE1 or PGE2.
  • PDE inhibitor is preferably a PDE5 or PDE6 inhibitor and said PG is PGE1 or PGE2.
  • said second agent is vardenafil, tadalafil, or sildenafil.
  • said co-medication comprises the use of BH4 or a salt thereof, and as said second agent sildenafil or vardenafil.
  • the present invention is inter alia based on experiments performed on male patients suffering from sexual dysfunction; see also Example 2.
  • the psychogenic component of male sexual dysfunction has been classified by the nomenclature committee of the International Society for Impotence Research (and is illustrated in Sachs, Neuroscience and Biobehavioral Review 24 (2000), 541-560) as generalized type, characterized by a general unresponsiveness or primary lack of sexual arousal, and ageing-related decline in sexual arousability, characterized by generalized inhibition or chronic disorders of sexual intimacy.
  • the inventors believe that there are common mechanisms underlying the pathologies of male and female psychogenic sexual dysfunctions.
  • compositions of the present invention described herein are useful in the treatment of male sexual dysfunction, especially erectile dysfunction and psychogenic male sexual dysfunction associated with generalized unresponsiveness and ageing-related decline in sexual arousability, in particular wherein said dysfunction is related to benign prostatic hyperplasia, erectile function and/or maintenance of functional and structural integrity of corpus cavemosum tissue.
  • Advantages of the present invention comprise inter alia that the treatment with NOS cofactors such as BH4, its precursors or its analogues, have only limited side effects.
  • BH4 is a causal therapy, directly linked to the impaired endothelial NOS activity leading to erectile dysfunction; in a BH4-saturated condition BH4 treatment has no further effects on NO release by endothelial NOS.
  • BH4 long-term effect of BH4 should also be considered, as previously shown for the prevention of tissue injury and facilitation of recovery in endothelial dysfunction and/or other chronic diseases (Pieper, J. Cardiovasc. Pharmacol. 29 (1997), 8-15; Meininger et al., Biochem. 349 (2000), 353-356; Sun et al, Am. J. Physiol. Heart Circ. Physiol. 281 (2002), 863-869).
  • the mode with which BH4 works also makes a combination therapy with other downstream therapeutics, e.g. PDE5 inhibitors, effective.
  • the pharmaceutical composition may be administered in accordance with the dosage regimen described above.
  • the administration of said composition to the female can be in a dosage which is in the range of from 0.1 to 500 mg/kg/day and wherein said administration is at intervals of 1 to 3 times a day during a period of at least 12 weeks; said treatment regimen may be combined and/or repeated at one or several intervals.
  • the dosage is in the range of 10 to 100 mg/kg/day.
  • the response rate to PDE5 inhibitors as a treatment for erectile dysfunction of purely organic origin is approx. 40-60 %. There are marked individual differences here, depending on the degree of severity of the damage in neuronal signaling and/or smooth muscle relaxation. Due to the systemic side effects (headache, flushing, nasal congestion, etc.) and contraindications (manifest cardiac insufficiency, nitrate co-medication) associated with PDE5 inhibitors, an increase in dosage is not always feasible, and the medication cannot be used at all for some patients. This results in the need to find an alternative medication for such patients, i.e.
  • medication or co-medication with NOS cofactors such as preferably BH4 offers a promising solution here.
  • the present invention comprises the use of a second agent capable of ameliorating sexual dysfunction for the preparation of a pharmaceutical composition, see also supra, wherein if said NOS cofactor and said second agent are comprised in a first and second pharmaceutical composition, said first and second pharmaceutical composition being applicable simultaneously or sequentially.
  • NOS cofactors such as BH4 are not toxic and have less side effects, if any, compared to drugs such as PDE5 inhibitors and PGEs used so far, the co-medication of a NOS cofactor in the treatment of sexual dysfunction provides an important advantage since contraindications of other drugs can be avoided while the overall beneficial effect remains substantially the same or may even be improved as well.
  • NOS cofactors can generally be used as part of a medicament in combination with one or more other therapeutic agents such as a vasodilator, hormone therapy or neurotransmitter modulator used or tested in the treatment of sexual dysfunction; see supra.
  • said second agent is preferably a phosphodiesterase (PDE) inhibitor, a prostaglandin (PG), papaverin, apomorphine or phentolamin, wherein said PDE inhibitor is preferably a PDE5 or PDE6 inhibitor and said PG is PGEl or PGE2.
  • PDE inhibitor is preferably a PDE5 or PDE6 inhibitor and said PG is PGEl or PGE2.
  • said second agent is vardenafil, tadalafil, or sildenafil.
  • said co- medication comprises the use of BH4 or a salt thereof, and as said second agent sildenafil, tadalafil, or vardenafil.
  • the present invention also relates to pharmaceutical compositions comprising a NOS cofactor as defined above and a second agent capable of ameliorating sexual dysfunction such as those described hereinbefore.
  • the present invention generally relates to the use of a NOS cofactor as defined herein, optionally in combination with a second agent capable of ameliorating sexual dysfunction such as those described hereinbefore, for the preparation of a pharmaceutical composition for improving female sexual function, desire and/or maintenance of functional and structural integrity of clitoral and vaginal tissue, for the treatment of benign prostatic hyperplasia, or for improving male erectile function and/or maintenance of functional and structural integrity of corpus cavemosum tissue.
  • the present invention relates to a method for improving female sexual function, desire and/or maintenance of functional and structural integrity of clitoral and vaginal tissue, for the treatment of benign prostatic hype ⁇ lasia, or for improving erectile function and/or maintenance of functional and structural integrity of co ⁇ us cavemosum tissue, comprising the step of administering to a subject having or suspected to get a sexual dysfunction a therapeutic amount a NOS cofactor as defined herein, optionally in combination with a second agent capable of ameliorating sexual dysfunction such as those described hereinbefore.
  • a further cause for sexual dysfunction in men can be benign prostatic hype ⁇ lasia.
  • Benign prostatic hype ⁇ lasia (BPH), a nonmalignant enlargement of the prostate, is the most common benign tumor in men. Approximately 50 % of all men older than 65 years have some degree of BPH and a third of these men have clinical symptoms consistent with bladder outlet obstruction (Hieble and Caine, Fed. Proc. 45 (1986), 2601).
  • benign and malignant diseases of the prostate are responsible for more surgery than diseases of any other organ in men over the age of fifty.
  • the static component is due to enlargement of the prostate gland, which may result in compression of the urethra and obstruction to the flow of urine from the bladder.
  • the dynamic component is due to increased smooth muscle tone of the bladder neck and the prostate itself (which interferes with emptying of the bladder) and is regulated by alpha 1 adrenergic receptors ([ ]l-ARs).
  • the medical treatments available for BPH address these components to varying degrees, and the therapeutic choices are expanding.
  • Surgical treatment options address the static component of BPH and include transurethral resection of the prostate (TURP), transurethral incision of the prostate (TUIP), open prostatectomy, balloon dilatation, hyperthermia, stents and laser ablation.
  • TURP is the preferred treatment for patients with BPH and approximately 320,000 TURPs were performed in the U.S. in 1990 at an estimated cost of $ 2.2 billion (Weis et al, Prostate 22 (1993), 325-334).
  • an effective treatment for most men with symptomatic BPH approximately 20-25 % of patients do not have a satisfactory long-term outcome (Lepor and Rigaud, J. Urol. 143 (1990), 533-537).
  • Complications include retrograde ejaculation (70-75 % of patients), impotence (5-10 %), postoperative urinary tract infection (5-10 %), and some degree of urinary incontinence (2-4 %) (Mebust et al., J. Urol. 141 (1989), 243-247). Furthermore, the rate of re-operation is approximately 15-20 % in men evaluated for 10 years or longer (Wennberg et al., JAMA 257 (1987), 933-936).
  • Finasteride Proscar (R) , Merck
  • This drug is a competitive inhibitor of the enzyme 5a-reductase which is responsible for the conversion of testosterone to dihydrotestosterone in the prostate gland (Gormley et al., N. Engl. J. Med. 327 (1992), 1185-1191).
  • Dihydrotestosterone appears to be the major mitogen for prostate growth, and agents which inhibit 5a-reductase reduce the size of the prostate and improve urine flow through the prostatic urethra.
  • finasteride is a potent 5a-reductase inhibitor and causes a marked decrease in serum and tissue concentrations of dihydrotestosterone, it is only moderately effective in treating symptomatic BPH (Oesterling, N. Engl. J. Med. 332 (1995), 99-109). The effects of finasteride take 6-12 months to become evident and for many men the clinical improvement is minimal (Barry et al., J. Urol. 158 (1997), 488-492).
  • adrenergic receptor blocking agents [ ⁇ ] l-AR blockers
  • [ ⁇ ] l-AR blockers adrenergic receptor blocking agents
  • terazosin, prazosin, and doxazosin adrenergic receptor blocking agents
  • doxazosin mesylate Cardura (C)
  • the [ ⁇ ]l-AR blockers are well-tolerated, approximately 10-15 % of patients develop a clinically adverse event (Lepor, J. Clin. Endocrinol. Metab.
  • saw palmetto extracts have been investigated; see for review, e.g., Gerber, J. Urol. 163 (2000), 1408-1412.
  • Various compositions comprising saw palmetto extract as well as a controlled delivery system is described in US patent application US2003/096024.
  • the treatment of benign prostatic hype ⁇ lasia with oral administration of 13 cis- retinoic acid has been described in WO03/024394.
  • the dynamic component is due to increased smooth muscle tone of the bladder neck and the prostate itself.
  • NO sexual dysfunction nitric oxide
  • the present invention relates to the use of a NOS cofactor as defined hereinabove as single or co-medication for the treatment of subvesical obstruction caused by prostatic hype ⁇ lasia or bladder neck sclerosis.
  • the formulation of the pharmaceutical compositions for the medication can be done as described for the preceding embodiments as well as concurrent or sequential administration of other therapeutic compounds; see supra.
  • administration of a NOS cofactor such as BH4 can be combined with any one of the afore described drugs for the treatment of BPH.
  • said co-medication is a prostate-selective medication such as described above, e.g., a prostate-selective alpha reductase inhibitor or alpha receptor inhibitor.
  • the present invention relates to the use of a NOS cofactor as defined herein as single or co-medication for the treatment of interstitial cystitis, low bladder capacity disorders or of micturition disorders as urge incontinence. It is understood that the entire description concerning the preparation of pharmaceutical compositions with one or more active ingredients described in the preceding sections also applies for the single and co-medication of those kinds of sexual dysfunction. In this respect, the uses, methods and compositions disclosed herein are described and preferably applied to humans.
  • the treatment of other mammals is envisaged and can be beneficial as well, in particular the treatment of domestic animals such as horses, cows, sheep, dogs, etc., wherein the treatment according to the present invention may help in animal breeding programs, but maybe also useful for helping keeping animal population, e.g., in the zoo, for example in case animals are hesitant to copulate because of hospitalization.
  • Example 1 Pharmaceutical compositions of the present invention for the treatment of sexual dysfunction
  • Pharmaceutical compositions for use in the present invention can be prepared according to known methods such as those described in the prior art referred to in the general section above.
  • Preferred formulations are, e.g., those described in Examples 1 to 9 of European patent application EP 0 908 182 A, the disclosure content of which is inco ⁇ orated herein by reference.
  • Particularly preferred compositions of the present invention are 10 mg and 50 mg (6R)-BH4 tablets.
  • Each 10 mg tablet contains (6R)-5,6,7,8-tetrahydro-L-biopterin dihydrochloride (6R- BH 4 -2HC1) , ascorbic acid, 5 mg N-acetyl-L-cysteine and other excipients (no lactose is added and no materials are used that are derived from animal or cell culture techniques).
  • Each 50 mg tablet contains 50 mg (6R)-5,6,7,8-tetrahydro-L-biopterin dihydrochloride (6R-BH -2HC1) , ascorbic acid, 25 mg N-acetyl-L-cysteine and other excipients (no lactose is added and no materials are used that are derived from animal or cell culture techniques).
  • Those tablets are particularly suited for oral administration of 1 to 20 mg tetrahydrobiopterin/kg/day. However, greater dosages can be used as well as described in Example 2.
  • the tablets can be dissolved in a little water, orange juice or other liquid, and mixed gently. Administration of the suspension is preferably done within 30 minutes. On the other hand, the tablets may be swallowed undissolved.
  • co-medication of a NOS cofactor and another therapeutic agent can be done, for example, by swallowing a 5 to 20 mg Levitra ⁇ (vardenafil) tablet with some water together or sequentially with a 10 to 50 mg BH4 tablet, see supra, preferably 20 to 60 minutes before the sexual activity. Similar comedication can be made with, for example, a 25, 50 or 100 mg Viagra ⁇ (sildenafil) tablet.
  • a BH4 and, e.g., silenafil or vardenafil composition may be present in the same composition or contained, e.g., as tablets in a kit.
  • NOS cofactor tetrahydrobiopterin BH4 increases penile rigidity and tumescence in erectile dysfunction patients
  • IIEF standardized questionnaire
  • Subjects with any of the following findings were excluded: ED known to be due to neurological or endocrine causes, or an anatomical deformity such as severe penile fibrosis, or a spinal cord injury or radical prostatectomy. Patients were excluded if they had diabetes mellitus, or any further relevant comorbidity or major psychiatric illness. Additionally, subjects were excluded if blood pressure and heart rate were too abnormal or other laboratory test results indicated a second or third degree AV-block, QRS duration > 120ms or QT interval >500 ms. Subjects were not allowed to be taking any other medication likely to interact with the compound under investigation.
  • Treatments were administered as oral drinking solutions containing either 10 mg, 20 mg, 50 mg, 100 mg, 200 mg or 500 mg of tetrahydrobiopterin, or a placebo solution. The medication was followed by 100 ml tap water. The investigated treatments were administered in the morning after a light breakfast.
  • the RigiScan (RigiScan Ambulatory Rigidity and Tumescence Monitor, Dacomed Co ⁇ ., Minneapolis, USA) was used to monitor penile rigidity and tumescence.
  • the subjects were connected to the RigiScan device from 0,5 h before until 3 h after dosing, using a conventional set-up with a cuff around the base and another around the tip of the penis.
  • Radial rigidity expressed as a percentage of complete rigidity, was determined automatically every 15 s by the device after internal calibration. Tumescence was also automatically calculated by the device.
  • the visual sexual stimulation consisted of sexually graphic videos (a set of different tapes was supplied to the subject from which he could select).
  • the subjects were instructed to try to prevent ejaculation and were asked not to stimulate themselves manually during the whole session.
  • the primary endpoint was the total duration of erections with greater than 60 % rigidity, as calculated using the RigiScan software. Secondary endpoints were duration of >80 % rigidity, Rigidity Activity Units (RAU) and Tumescence Activity Units (TAU) (Benet et al., J. Urol. 156 (1996), 1947-1950).
  • RAU Rigidity Activity Units
  • TAU Tumescence Activity Units
  • the average erection rigidity, duration of event, circumference and average event tumescence were evaluated as ancillary criteria. All values were calculated separately for the base and the tip of the penis.
  • AEs Adverse events
  • the duration was statistically significantly prolonged up to 59,2 min and 53,1 min at the base and the tip of the penis, respectively (P ⁇ 0,01). Similary, the 100-mg dose showed marked prolongation of the time that the penis exceeded 60 % rigidity compared with that of the placebo, reaching 69,5 min and 64,9 min at the base and tip, respectively (P ⁇ 0,001). With 200 mg tetrahydrobiopterin, the duration was statistically significantly prolonged up to 78,6 min and 67,4 min at the base and the tip of the penis, respectively (P ⁇ 0,01).
  • Nitric oxide synthase catalyses the production of NO and L-citrulline from L-arginine, O 2 , and NADPH-derived electrons.
  • NOS utilizes 6 different cofactors and prosthetic groups: thiolate- bound heme, FAD and FMN, calmodulin Ca 2+ , (6R)-5,6,7,8-tetrahydro-L-biopterin (BH4), and Zn 2+ .
  • NOS catalyses the formation of NO in two consecutive steps.
  • First L-arginine is oxidized to N- hydroxy-L-arginine (NHA), in a reaction that consumes one molecule of O 2 and two NADPH- derived electrons.
  • NHA is converted into L-citrulline and NO with consumption of one more NADPH-derived electrons and another molecule of O 2 (Stuehr et al., J. Biol. Chem. 266 (1991), 6259-6263).
  • the gene for NOS was found to contain a binding site for (6R)-L-erythro-5, 6,7,8- tetrahydrobiopterin (also referred to as "BH4" and "BH " interchangeably herein) included in compounds of the formula (I) below as active ingredients of the present invention, in addition to those for coenzymes such as calmodulin (CaM), flavin, NADPH.
  • BH4 and BH calmodulin
  • NOS will oxidize NADPH in the absence of substrate or pterin, but in that case the reaction products are O 2 * and H 2 O 2 .
  • NOS itself can be a potential source for endothelial production of oxygen free radicals and that decreased availability of BH4 might cause a shift in balance between ability of protective NO and toxic oxygen free radicals
  • a further reduction of avaible NO occurs by the reaction of oxygen free radicals as O 2 - and H 2 O 2 with NO.
  • One of the reaction products is peroxynitrite, which leads in comparison to NO to a opposite contractile effect on vascular smooth muscle (for review Dr ⁇ ge, Physiol. Rev. 82 (2002), 47-95).
  • exogenous BH4 has been shown to reduce post-ischemic endothelial dysfunction, post-transplantation lung edema, ischemia reperfusion injury and OFR injury in grafts, and ischemic renal injury (Tiefenbacher et al., Circulation 102 (1996), 2172-2179; Schmid et al., J. Thorac. Cardiovasc. Surg. 118 (1999), 726-732; Kakoki et al., J. Am. Soc. Nephrol. 1 1 (2000), 301-309; Yamashiro et al., J. Thorac. Cardiovasc. Surg. 124 (2002), 775- 784).
  • An increased production of oxygen radicals and peroxynitrite can be investigated in human tissue by detection of radical reaction products such as 8-isoprostane for oxygen radicals and nitrotyrosine for peroxynitrite (Viera et al., Methods Enzymol. 301 (1999), 373-381 ; Morrow, Drug Metab. Rev. 32 (2000), 377-385). Recently, an immunohistochemical increase of 8- isoprostane and nitrotyrosine formation during cardiac surgery in human heart could be detected (Mehlhom et al, J. Thorac. Cardiovasc. Surg. 125 (2002), 178-183).
  • oxidative stress mediated through the superoxide radical (superoxide) and other reactive oxygen species (ROS) may be central to impaired cavernosal function in erectile dysfunction (ED).
  • Increased inactivation of NO by superoxide results in impaired penile NO transmission and smooth muscle relaxation.
  • propagation of endothelial dysfunction by ROS may result in chronic impairment of penile vascular function, a process analogous to early atherogenesis.
  • ED and atherosclerosis are closely linked through shared risk factors.
  • antioxidants may be of benefit in both the short- and long-term treatment. This gives evidence that antioxidant therapy can be used for prevention or treatment of ED (Jones et al., Expert Opin. Pharmacother. 3 (2002), 889-897).
  • the present invention provides novel uses and compositions that effectively prevent and/or ameliorate sexual dysfunction.
  • the active ingredients of the pharmaceutical compositions of the present invention based on NOS cofactor, in particular BH4 and derivatives thereof have no adverse effects or the like over long- term use because they are substances that inherently exist in vivo.

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des compositions et des méthodes pour traiter le dysfonctionnement sexuel chez un mammifère, y compris le dysfonctionnement sexuel masculin tel que la dysérection et le dysfonctionnement sexuel féminin. La présente invention porte notamment sur l'utilisation d'un cofacteur NOS dans la préparation d'un médicament pour traiter et/ou prévenir le dysfonctionnement sexuel.
PCT/EP2004/009543 2003-08-26 2004-08-26 Utilisation d'un cofacteur de synthase d'oxyde nitrique (nos) pour traiter le dysfonctionnement sexuel WO2005018620A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03019309.8 2003-08-26
EP03019309 2003-08-26

Publications (2)

Publication Number Publication Date
WO2005018620A2 true WO2005018620A2 (fr) 2005-03-03
WO2005018620A3 WO2005018620A3 (fr) 2005-07-28

Family

ID=34203226

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/009543 WO2005018620A2 (fr) 2003-08-26 2004-08-26 Utilisation d'un cofacteur de synthase d'oxyde nitrique (nos) pour traiter le dysfonctionnement sexuel

Country Status (1)

Country Link
WO (1) WO2005018620A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007067570A1 (fr) * 2005-12-05 2007-06-14 Biomarin Pharmaceutical Inc. Procédés et compositions pour le traitement d'une maladie
WO2007072156A1 (fr) * 2005-12-21 2007-06-28 Pfizer Products Inc. Combinaison pharmaceutique d'un inhibiteur de pde-5 et d'un inhibiteur de 5-alpha reductase

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997030066A1 (fr) * 1996-02-15 1997-08-21 Gonzalez Cadavid Nestor F Nouvelle synthase de l'oxyde nitrique des neurones propres au penis, et utilisations diagnostiques et therapeutiques concernant des troubles urogenitaux
EP0908182A1 (fr) * 1996-08-30 1999-04-14 Suntory Limited Preparations servant a la prevention et au traitement de maladies provoquees par une hypofonction de l'oxyde nitrique synthase
WO2001028541A2 (fr) * 1999-10-19 2001-04-26 Shlomo Laniado Preparation de sildenafil
WO2001056551A2 (fr) * 2000-01-31 2001-08-09 University Of Zurich Formulation et procede utilises dans le traitement de la vasoconstriction
WO2002064146A1 (fr) * 2001-02-13 2002-08-22 Aventis Pharma Deutschland Gmbh 4-fluoro-n-indan-2-yle benzamide et son utilisation comme agent pharmaceutique
WO2002076481A1 (fr) * 2001-03-26 2002-10-03 Niazi Sarfaraz K Composition et procede s'utilisant dans le traitement de dysfonctionnements sexuels au moyen d'inhibiteurs de phosphodiesterase de type 5 specifiques de gmp cyclique
WO2004017955A1 (fr) * 2002-08-22 2004-03-04 Vasopharm Biotech Gmbh Composition pharmaceutique contenant de la l-arginine

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997030066A1 (fr) * 1996-02-15 1997-08-21 Gonzalez Cadavid Nestor F Nouvelle synthase de l'oxyde nitrique des neurones propres au penis, et utilisations diagnostiques et therapeutiques concernant des troubles urogenitaux
EP0908182A1 (fr) * 1996-08-30 1999-04-14 Suntory Limited Preparations servant a la prevention et au traitement de maladies provoquees par une hypofonction de l'oxyde nitrique synthase
WO2001028541A2 (fr) * 1999-10-19 2001-04-26 Shlomo Laniado Preparation de sildenafil
WO2001056551A2 (fr) * 2000-01-31 2001-08-09 University Of Zurich Formulation et procede utilises dans le traitement de la vasoconstriction
WO2002064146A1 (fr) * 2001-02-13 2002-08-22 Aventis Pharma Deutschland Gmbh 4-fluoro-n-indan-2-yle benzamide et son utilisation comme agent pharmaceutique
WO2002076481A1 (fr) * 2001-03-26 2002-10-03 Niazi Sarfaraz K Composition et procede s'utilisant dans le traitement de dysfonctionnements sexuels au moyen d'inhibiteurs de phosphodiesterase de type 5 specifiques de gmp cyclique
WO2004017955A1 (fr) * 2002-08-22 2004-03-04 Vasopharm Biotech Gmbh Composition pharmaceutique contenant de la l-arginine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HELLER REGINE ET AL: "L-ascorbic acid potentiates endothelial nitric oxide synthesis via a chemical stabilization of tetrahydrobiopterin" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 1, 5 January 2001 (2001-01-05), pages 40-47, XP002320050 ISSN: 0021-9258 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007067570A1 (fr) * 2005-12-05 2007-06-14 Biomarin Pharmaceutical Inc. Procédés et compositions pour le traitement d'une maladie
WO2007072156A1 (fr) * 2005-12-21 2007-06-28 Pfizer Products Inc. Combinaison pharmaceutique d'un inhibiteur de pde-5 et d'un inhibiteur de 5-alpha reductase

Also Published As

Publication number Publication date
WO2005018620A3 (fr) 2005-07-28

Similar Documents

Publication Publication Date Title
Tam et al. Yohimbine: a clinical review
Goldenberg Safety and efficacy of sildenafil citrate in the treatment of male erectile dysfunction
Burnett The role of nitric oxide in erectile dysfunction: implications for medical therapy
Lue Erectile dysfunction
US20100267736A1 (en) Methods and compositions to enhance the efficacy of phosphodiesterase inhibitors
RU2464027C2 (ru) Применение 3-альфа-андростендиола, необязательно в сочетании с ингибитором фосфодиэстеразы 5, при лечении половой дисфункции
Alwaal et al. Future prospects in the treatment of erectile dysfunction: focus on avanafil
US20060030622A1 (en) Compounds and methods for the treatment of urogenital disorders
Steers et al. Assessment of the efficacy and safety of Viagra®(sildenafil citrate) in men with erectile dysfunction during long-term treatment
Nandipati et al. Erectile dysfunction following radical retropubic prostatectomy: epidemiology, pathophysiology and pharmacological management
CA2315871C (fr) Procedes, compositions et trousses pour stimuler le desir et la sensibilite sexuels chez la femme
Dhir et al. Combination therapy for erectile dysfunction: an update review
US6338862B1 (en) Composition and method of use in treating sexual dysfunction using cGMP-specific phosphodiesterase type 5 inhibitors
Lin et al. KMUP‐1 relaxes rabbit corpus cavernosum smooth muscle in vitro and in vivo: involvement of cyclic GMP and K+ channels
MCAULEY et al. Intracavernosal sildenafil facilitates penile erection independent of the nitric oxide pathway
US7754767B2 (en) Method for treatment of premature ejaculation in humans
Bella et al. Tadalafil in the treatment of erectile dysfunction
WO2005018620A2 (fr) Utilisation d'un cofacteur de synthase d'oxyde nitrique (nos) pour traiter le dysfonctionnement sexuel
US20130210867A1 (en) Methods and compositions for enhancing female sexual arousal and treating female sexual dysfunction
de Mey Opportunities for the treatment of erectile dysfunction by modulation of the NO axis-alternatives to sildenafil citrate
Ückert et al. Potential future options in the pharmacotherapy of female sexual dysfunction
Broderick Intracavernous pharmacotherapy: treatment for the aging erectile response
Kalsi et al. Novel PDE5 inhibitors for the treatment of male erectile dysfunction
Tome et al. Possible involvement of nitric oxide in pilocarpine induced seminal emission in rats
Kilicarslan et al. The effect of chronic renal failure on phosphodiesterase inhibitor-induced relaxation responses in rabbit cavernosal strips

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase